Moderna Inc. applied for U.S. emergency authorization for the company’s Covid-19 vaccine after full results from a late-stage study showed mRNA-1273 was 94.1% effective with no serious safety concerns.

Moderna announced plans to submit the company’s request to the U.S. Food and Drug Administration for an Emergency Use Authorization (EUA) for the Covid-19 vaccine mRNA-1273 on Nov. 30.

With both Pfizer-BioNTech and Moderna’s Covid-19 vaccines at the U.S. Food and Drug Administration awaiting potential Emergency Use Authorization (EUA), airlines are preparing their cargo operations to ship the vaccines.

Ten Covid-19 vaccines could be available by the middle of 2021 if they win regulatory approval, but their inventors need patent protection, the head of the global pharmaceutical industry group said.

U.S. officials plan to release 6.4 million Covid-19 vaccine doses nationwide in an initial distribution after the first one is cleared by regulators for emergency use.

AstraZeneca said on Monday the company’s Covid-19 vaccine could be as much as 90% effective, giving the world’s fight against the global pandemic a new weapon, cheaper to make, easier to distribute and faster to scale-up than rivals.

U.S. healthcare workers and others recommended for the nation’s first Covid-19 inoculations could start getting shots within a day or two of regulatory consent in December, a top official of the government’s vaccine development effort said.

Pfizer Inc. applied to U.S. health regulators for emergency use authorization (EUA) of the company’s Covid-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus.

With all the expectations for available Covid-19 vaccines based on the successful late-stage trial results reported by Pfizer/BioNTech and Moderna, the looming question is: when will the public be able to start getting the vaccines?

U.S. and European regulators could approve Pfizer and BioNTech’s experimental Covid-19 vaccine as early as mid-December, the German firm’s chief executive said, following the release of positive trial results.